Richard Scott Struthers - 23 Feb 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Tobin Schilke, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
23 Feb 2026
Net transactions value
$0
Form type
4
Filing time
25 Feb 2026, 16:37:01 UTC
Previous filing
18 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Struthers Richard Scott President & CEO, Director C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke, as attorney-in-fact 25 Feb 2026 0001746298

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +62,000 +17% $0.000000 426,759 23 Feb 2026 Direct F1
holding CRNX Common Stock 661,205 23 Feb 2026 By Family Trust 1
holding CRNX Common Stock 106,000 23 Feb 2026 By Family Trust 2
holding CRNX Common Stock 110,000 23 Feb 2026 By Family Trust 3
holding CRNX Common Stock 100,000 23 Feb 2026 By Family Trust 4
holding CRNX Common Stock 1,000 23 Feb 2026 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Award $0 +228,000 $0.000000 228,000 23 Feb 2026 Common Stock 228,000 $43.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.